FDA approves new COVID shots - with same restrictions as las...
FDA has approved the 2026 COVID vaccine formulations, but last year's narrower recommendation stands, leaving open questions about access.
Sword Health buys Headspace in $200M to $300M deal
Digital mental health company Headspace will be acquired by Sword Health next month, according to regulatory filings.
Biotech funding has returned. The bar has moved with it.
For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
Building a Phase I oncology centre
The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
AI, Forecasting, Insights and Analytics for Smarter Decision...
Learn from case studies, expert-led panels, roundtable discussions, and interactive workshops on Gen AI-powered forecasting
30th Portfolio Decision-Making & Prioritisation for Pharma
Pharmaceutical portfolio decision-making is facing structural pressure.
R&D Governance, Controlling and Innovation for Pharma
The Marcus Evans R&D Governance, Controlling, and Innovation for Pharma conference will take place at the Crowne Plaza - Frankfurt Congress Hotel
The MFN effect: what payers expect and how Pharma should res...
A live webinar and audience Q&A with practical insights from global payer research and leading payer experts
The Pharmaceutical Launch Excellence Summit
Where pharma leaders share strategies for successful drug launches.